按皮肤受累状态分层的乳房切除术后放疗中组织等效填充物处方随机临床试验
这项随机临床试验纳入58例需乳房切除术后放疗的乳腺癌患者,按皮肤受累分为标准风险组和高风险组,分别比较不同填充物方案。结果显示每日5 mm填充物显著增加总体毒性负担,而较低强度填充物方案在同一风险组内未检测到胸壁局部控制受损。
要点
- 标准风险组无填充物与隔日5 mm填充物组G2放射性皮炎发生率无差异(p=0.70),无G3事件。
- 高风险组每日填充物较隔日填充物G2(100% vs 44.5%,p=0.01)和G3放射性皮炎(70% vs 11.1%,p=0.02)发生率更高。
- 中位随访6.2年,标准风险组5年局部控制率95.8%(95%CI:88.2%-100%),高风险组91.7%(95%CI:77.3%-100%)。
核心结论
- 每日5 mm填充物处方显著增加总体毒性负担。
- 在这项初步研究中,同一风险组内较低强度填充物方案(标准风险组:无填充物;高风险组:隔日填充物)未检测到胸壁局部控制受损。
- 放射性皮炎特异性毒性指数(rads-TI)能够区分总体放射性皮炎负担。
研究设计与样本
- 随机临床试验(NCT01925651),纳入58例需乳房切除术后放疗的乳腺癌患者,分为标准风险组(无皮肤受累,34例)和高风险组(有皮肤受累,24例)。
- 标准风险组随机接受无填充物或隔日5 mm填充物;高风险组随机接受隔日5 mm填充物或每日5 mm填充物。
- 采用常规分割放疗(50.4 Gy;1.8 Gy/日),急性皮肤毒性盲法评估并计算rads-TI,随后随访评估肿瘤学结局,重点关注胸壁局部控制。
主要发现
- 总体最大放射性皮炎发生率为G2 29.4%和G3 15.7%。
- 标准风险组亚组间G2放射性皮炎发生率无差异(p=0.70),无G3事件发生。
- 高风险组每日填充物较隔日填充物G2(100% vs 44.5%,p=0.01)和G3放射性皮炎(70% vs 11.1%,p=0.02)发生率更高。
- 调整混杂因素后,每日填充物G2(p=0.03)、G3放射性皮炎(p=0.04)发生率更高且rads-TI更差(p<0.01)。
- 中位随访6.2年,标准风险组5年局部控制率95.8%(95%CI:88.2%-100%),高风险组91.7%(95%CI:77.3%-100%);按风险组分层,标准风险组(p=0.90)和高风险组(p=0.70)内不同填充物方案间局部控制无差异。
局限性
- 原文称该研究为初步研究(preliminary study)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the impact and optimize the prescription of tissue-equivalent bolus in postmastectomy radiotherapy (PMRT), we compared the use of different bolus regimens tailored by skin involvement status. METHODS: Patients with breast cancer who required PMRT were recruited (NCT01925651) and classified into two groups: standard-risk (SR, without skin involvement) and high-risk (HR, with skin involvement). SR was randomized between no bolus or 5 mm-bolus on alternate days and HR between 5 mm-bolus on alternate days or daily. Conventional fractionation (50.4 Gy; 1.8 Gy/daily) was used. Acute skin toxicity was evaluated blindly and the radiodermatitis-specific toxicity index [rads-TI] calculated. Subsequently, patients were followed up to assess oncologic outcomes, focusing on chest wall (CW) local control. RESULTS: Fifty-eight patients were enrolled (34 SR and 24 HR). Baseline characteristics were similar between arms within the same risk group. Overall, maximal radiodermatitis rates were 29.4 % (G2) and 15.7 % (G3). In the SR group, no difference existed in G2 radiodermatitis incidence between the subgroups (p = 0.70) and no G3 events occurred. In the HR group, incidences of G2 (100 % vs 44.5 %, p = 0.01) and G3 radiodermatitis (70 % vs 11.1 %, p = 0.02) were higher with daily bolus. After adjusting for confounders, the daily bolus had a higher incidence of G2 (p = 0.03), G3 radiodermatitis (p = 0.04), and worse rads-TI (p < 0.01). After a median follow-up of 6.2 years, the 5-year local control was 95.8 % (95 %CI: 88.2 %-100 %) in the SR and 91.7 % (95 %CI: 77.3 %-100 %) in the HR groups. Per risk group, there was no difference in local control between the SR (p = 0.90) or the HR bolus regimens (p = 0.70). CONCLUSION: Daily 5 mm bolus prescription significantly increased the overall toxicity burden. In this preliminary study, within the same risk group, no detriment in CW local control was detected with less intense bolus regimens (SR: no bolus; HR: alternate-days bolus). Additionally, the rads-TI was able to distinguish overall radiodermatitis burden.
引用
- Sapienza LG, Maia MAC, Gomes MJL, et al. Randomized clinical trial of tissue equivalent bolus prescription in postmastectomy radiotherapy stratified by skin involvement status. Clin Transl Radiat Oncol. 2022. PMID: 36594077. doi:10.1016/j.ctro.2022.100570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。